



# AN INCLUSIVE CANADIAN APPROACH TO GENOMIC-BASED RNA THERAPEUTICS

With a landmark \$165 million investment from the Canada First Research Excellence Fund and additional support from the Quebec Government and philanthropic and industry partners, McGill's world-leading research initiative **D2R** will develop revolutionary genomic-based RNA medicines for all.

**Vision:** To deliver genomic-based RNA therapies to benefit the health of different populations who are affected by infectious, rare and neglected diseases, or common chronic diseases such as cancer.

**Mission:** To develop an internationally leading initiative in the discovery and development of genome-guided, RNA-based precision medicines, associated computational tools, along with a clinical accelerator to ensure application of its discoveries for all Canadians and for the world.

## Strategic Objectives



**Enable discovery:** D2R will overcome scientific and technical obstacles to realize the potential of genome-guided precision medicine and RNA therapies.



**Make an impact:** To realize the potential of genomic discovery and capitalize on the flexibility of RNA therapeutics, D2R is implementing an interdisciplinary research strategy to tackle priority disease areas.



**Engage partners:** D2R will be a hub for world-leading "next-generation" drug development in Canada, bringing together pharma and biotech to accelerate regulatory approval of life saving drugs. D2R's scope and Canada's competitiveness in these areas will be advanced through strong international links with leading biomedical research institutions in Europe, North America, Africa, and Asia.



**Drive equitable practice:** D2R will engage and consult with patient associations, Indigenous communities, and other equity-deserving groups to guide research and policy recommendations.





## D2R Network

A unique network of internationally recognized experts working together.

- Researchers from McGill and partner institutions (Université de Sherbrooke, University of British Columbia, University of Ottawa, McMaster University)
- Private sector companies
- Academic institutions
- Public sector, funding agencies, and knowledge mobilization organizations
- Indigenous organizations
- Major philanthropic donors

## Priority diseases

D2R's research will focus initially on three disease areas:

- Infectious diseases
- Oncology
- Rare diseases

## Foundational axes

D2R's axes guide the search for scientific breakthroughs and show strong commitment to inclusivity and meeting the varied needs of the community:

- Population Studies and Genomic Medicine
- RNA Therapeutics
- Bioprocessing, Biomanufacturing and Nanotechnology
- Clinical Research, Acceleration and Implementation
- Data Science, Bioinformatics and Computing in Personalized Medicine
- Ethical, Socioeconomic, and Cultural Dimensions in Genomic Research

## For more information:

[mcgill.ca/D2R](https://mcgill.ca/D2R)

## Questions?

[D2R@mcgill.ca](mailto:D2R@mcgill.ca)